
    
      A randomized, double-blind, active-controlled multicenter, two-way crossover study of HFA
      levalbuterol (with and without a spacer) in subjects 4-11 years of age with asthma. This
      study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by
      Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion
      Pharmaceuticals Inc.
    
  